Publications by authors named "E I Sigal"
This prospective, case-control study evaluated the impact of obesity on oocyte quality based on mtDNA expression in cumulus cells (CC), and on bone morphogenetic protein 15 (BMP-15) and heparan sulfate proteoglycan 2 (HSPG2) in follicular fluid (FF). It included women 18 to <40 years of age, divided according to BMI < 24.9 (Group 1, n = 28) and BMI > 25 (Group 2, n = 22).
View Article and Find Full Text PDFArticle Synopsis
- The IGF system is crucial in regulating growth and invasiveness in epithelial ovarian cancer (EOC) and is considered a potential target for therapy, although its role in the immune response within the EOC microenvironment is not well understood.
- The study tested the hypothesis that inhibiting the IGF1 receptor (IGF1R) alongside PD-1 would impact dendritic cell maturation and the EOC environment.
- Results showed that the combined treatment reduced tumor weight and increased immune responses, suggesting that targeting IGF1R and PD-1 together could be an effective strategy for treating certain EOC patients.
Article Synopsis
- Death rates for non-small cell lung cancer (NSCLC) have decreased by over 6% recently, largely due to advancements in treatment methods that improve survival rates.
- New drugs targeting molecular changes in NSCLC and immune-modulating treatments have shown promise in effectively attacking cancer cells.
- The FDA emphasized the need for a comprehensive and efficient approach to identify suitable patients for new therapies, leading to the development of the Lung Cancer Master Protocol to streamline clinical research for these treatments.
Purpose: Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established infrastructure for conducting a biomarker-driven master protocol in molecularly targeted therapies. We compared characteristics of patients enrolled in Lung-MAP with those of patients in advanced non-small-cell lung cancer (NSCLC) trials to examine if master protocols improve trial access.
Methods: We examined patients enrolled in Lung-MAP (2014-2020) according to sociodemographic characteristics.
Background: An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality of life (QOL). We compared QOL in patients enrolled to SWOG S1400I, a substudy of the LungMAP biomarker-driven master protocol.
Methods: SWOG S1400I was a randomized phase III trial comparing nivolumab plus ipilimumab vs nivolumab for treatment of immunotherapy-naïve disease in advanced squamous cell lung cancer.